J. Listing

发表

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

M. Dougados, D. M. van der Heijde, R. Landewé, 2009, Annals of the rheumatic diseases.

MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis

J. Braun, J. Listing, J. Sieper, 2007, Annals of the rheumatic diseases.

Open label trial of anakinra in active ankylosing spondylitis over 24 weeks

J. Listing, J. Sieper, H. Haibel, 2004, Annals of the rheumatic diseases.

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

P. Tugwell, M. Dougados, M. D. de Wit, 2011, Annals of the rheumatic diseases.

Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis

H. Zeidler, G. Burmester, G. Burmester, 2004, Annals of the rheumatic diseases.

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial

Andreas Krause, G. Burmester, A. Krause, 2011, Annals of the rheumatic diseases.

Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography

M. Dougados, D. M. van der Heijde, R. Landewé, 2013, Annals of the rheumatic diseases.

Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.

J. Braun, J. Brandt, J. Listing, 2005, Rheumatology.

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab

J. Braun, J. Brandt, J. Listing, 2005 .

Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept

J. Braun, J. Brandt, J. Listing, 2005, Annals of the rheumatic diseases.

Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems

D. M. van der Heijde, W. Golder, J. Braun, 2004, Annals of the rheumatic diseases.

Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.

H. Zeidler, G. Burmester, W. Golder, 2003, Arthritis and rheumatism.

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal

M. Dougados, B. Dijkmans, I. Olivieri, 2009, Annals of the rheumatic diseases.

ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis

D. M. van der Heijde, R. Landewé, D. Heijde, 2008, Annals of the rheumatic diseases.

Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

M. Aringer, J. Listing, A. Zink, 2016, Annals of the rheumatic diseases.

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.

D. M. van der Heijde, J. Braun, J. Listing, 2007, Arthritis and rheumatism.

Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response

Andreas Krause, H. Zeidler, G. Burmester, 2007, Annals of the rheumatic diseases.

Impact of anti-tumour necrosis factor α treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis

J. Braun, J. Brandt, J. Listing, 2004, Annals of the rheumatic diseases.

Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.

H. Zeidler, G. Burmester, G. Burmester, 2005, Rheumatology.

Treatment continuation in patients receiving biological agents or conventional DMARD therapy

R. Rau, S. Wassenberg, E. Gromnica-ihle, 2005, Annals of the rheumatic diseases.

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

P. Tugwell, M. Dougados, M. D. de Wit, 2011, Arthritis and rheumatism.

Comparative effectiveness of tumour necrosis factor α inhibitors in combination with either methotrexate or leflunomide

J. Listing, A. Zink, H. Tony, 2009, Annals of the rheumatic diseases.

Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial

J. Braun, J. Listing, J. Sieper, 2013, Annals of the rheumatic diseases.

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.

D. M. van der Heijde, W. Golder, J. Braun, 2003, Arthritis and rheumatism.

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab

J. Braun, J. Braun, J. Brandt, 2005, Arthritis Research & Therapy.

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis

J. Braun, J. Brandt, J. Listing, 2004, Annals of the rheumatic diseases.

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

P. Tugwell, M. Dougados, M. D. de Wit, 2011, Arthritis and rheumatism.

Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes

J. Braun, J. Brandt, J. Listing, 2007, Annals of the rheumatic diseases.

Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change.

J. Braun, J. Listing, J. Sieper, 2009, Arthritis and rheumatism.

Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences

R. Landewé, J. Brandt, X. Baraliakos, 2005, Annals of the rheumatic diseases.

Blood pressure- and lipid-lowering effect of mackerel and herring diet in patients with mild essential hypertension.

M. Wirth, C. Taube, J. Listing, 1985, Atherosclerosis.

Incidence and prevalence of juvenile chronic arthritis in East Berlin 1980-88.

J. Meincke, J. Listing, A. Zink, 1998, The Journal of rheumatology.

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

A. Strangfeld, T. Klopsch, H. Bergerhausen, 2011, Annals of the rheumatic diseases.

Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.

J. Braun, J. Brandt, J. Listing, 2005, Rheumatology.

Radiographic progression in patients with ankylosing spondylitis after two years of treatment with the tumor necrosis factor-α antibody infliximab

J. Brandt, X. Baraliakos, M. Rudwaleit, 2005 .

A comparison of new bone formation in patients with ankylosing spondylitis and patients with diffuse idiopathic skeletal hyperostosis: a retrospective cohort study over six years.

J. Buschmann, J. Braun, J. Listing, 2012, Arthritis and rheumatism.

Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.

J. Braun, J. Listing, J. Sieper, 2010, Arthritis and rheumatism.

Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations

J. Listing, J. Sieper, M. Rudwaleit, 2008, Annals of the rheumatic diseases.

Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab.

J. Braun, J. Brandt, J. Listing, 2007, Rheumatology.

Evaluation of the RABBIT Risk Score for serious infections

A. Krause, J. Listing, A. Zink, 2013, Annals of the rheumatic diseases.

Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial.

N. Mitchison, F. Hiepe, J. Braun, 1996, Arthritis and rheumatism.

The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab.

M. Dougados, P. Geusens, R. Landewé, 2011, Clinical and experimental rheumatology.

Atopic disorders in ankylosing spondylitis and rheumatoid arthritis

J. Braun, J. Listing, A. Zink, 2002, Annals of the rheumatic diseases.

Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.

J. Braun, J. Brandt, J. Listing, 2005, Arthritis and rheumatism.

Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis

J. Braun, J. Sieper, J. Listing, 2010, Annals of the rheumatic diseases.